Is teicoplanin a complementary treatment option for COVID-19? The question remains
Giancarlo Ceccarelli(International Organization for Migration), Mario Venditti(Sapienza University of Rome), Franco Ruberto(Sapienza University of Rome), Francesco Alessandri(Sapienza University of Rome), Claudio Maria Mastroianni(Sapienza University of Rome), Francesco Pugliese(Sapienza University of Rome), Cristian Borrazzo(Sapienza University of Rome), Ornella Spagnolello(Policlinico Umberto I), Alessandra Oliva(Sapienza University of Rome), Gabriella d’Ettorre(Policlinico Umberto I)
Cited by 52
Related Papers
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
|The Lancet Infectious Diseases|2017|521
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review
|International Journal of Environmental Research and Public Health|2021|272